Background The emergence and rapid spread of SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) in thelate 2019 has caused a devastating global pandemic of the severe pneumonia-like disease coronavirus disease 2019 (COVID-19). Although vaccines have been and are being developed, they are not accessible to everyone and not everyone can receive these vaccines. Also, it typically takes more than 10 years until a new therapeutic agent is approved for usage. Therefore, repurposing of known drugs can lend itself well as a key approach for significantly expediting the development of new therapies for COVID-19. Methods We have incorporated machine learning-based computational tools and in silico models into the drug discovery process to predict Adsorption, Distribution, Metabolism, Excretion, and Toxicity (ADMET) profiles of 90 potential drugs for COVID-19 treatment identified from two independent studies mainly with the purpose of mitigating late-phase failures because of inferior pharmacokinetics and toxicity. Results Here, we summarize the cardiotoxicity and general toxicity profiles of 90 potential drugs for COVID-19 treatment and outline the risks of repurposing and propose a stratification of patients accordingly. We shortlist a total of five compounds based on their non-toxic properties. Conclusion In summary, this manuscript aims to provide a potentially useful source of essential knowledge on toxicity assessment of 90 compounds for healthcare practitioners and researchers to find off-label alternatives for the treatment for COVID-19. The majority of the molecules discussed in this manuscript have already moved into clinical trials and thus their known pharmacological and human safety profiles are expected to facilitate a fast track preclinical and clinical assessment for treating COVID-19. Supplementary Information The online version contains supplementary material available at 10.1186/s40360-021-00519-5.
【저자키워드】 COVID-19, Toxicity, Repurposing drugs, hERG), 【초록키워드】 Treatment, coronavirus disease, Stratification, SARS-CoV-2, Coronavirus disease 2019, Vaccine, coronavirus, clinical trial, therapy, Drug discovery, Vaccines, knowledge, clinical trials, risk, Toxicity, repurposing, drug, in silico, severe acute respiratory syndrome Coronavirus, metabolism, global pandemic, COVID-19 treatment, Spread, healthcare, therapeutic, Patient, therapeutic agent, severe pneumonia, respiratory, molecules, disease, predict, safety profile, Cardiotoxicity, clinical assessment, acute respiratory syndrome, supplementary material, acute respiratory syndrome coronavirus, acute respiratory syndrome coronavirus 2, Usage, profile, Compound, treating COVID-19, manuscript, excretion, off-label, researcher, pharmacological, Practitioner, approach, FIVE, independent, non-toxic, Result, caused, significantly, approved, facilitate, majority, expected, receive, computational tool, treatment for COVID-19, 【제목키워드】 risk, approved drug, demonstrated,